Although we did not have sequencing data available from the original tumor of patient #26, the #26 PDO had mutations typically present in breast cancer, such as mutations in BRCA2, FGFR2, and PMS2 (Fig. 2C). This evidence concerns the gene BRCA2 and breast cancer.